An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

SIMPLE SUMMARY: Neoadjuvant chemotherapy (NAC) is widely used to treat stage II and III primary, operable triple-negative breast cancer (TNBC). The response to NAC critically affects the subsequent treatment plan, including not only curative surgical planning but also adjuvant therapy. There is no s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Wai-Shan, Chen, Shin-Cheh, Ko, Tai-Ming, Lin, Yung-Chang, Lin, Sheng-Hsuan, Lo, Yung-Feng, Tseng, Shu-Chi, Yu, Chi-Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454735/
https://www.ncbi.nlm.nih.gov/pubmed/36077706
http://dx.doi.org/10.3390/cancers14174170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454735/
https://www.ncbi.nlm.nih.gov/pubmed/36077706
http://dx.doi.org/10.3390/cancers14174170

Ejemplares similares